Triple
T22796992
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | AveXis |
E564274
|
entity |
| Predicate | receivedApprovalFor |
P121137
|
FINISHED |
| Object | onasemnogene abeparvovec |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: onasemnogene abeparvovec | Statement: [AveXis, receivedApprovalFor, onasemnogene abeparvovec]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: onasemnogene abeparvovec Context triple: [AveXis, receivedApprovalFor, onasemnogene abeparvovec]
-
A.
onasemnogene abeparvovec
chosen
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
B.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
C.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
D.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
E.
GIVLAARI (givosiran)
GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: receivedApprovalFor Context triple: [AveXis, receivedApprovalFor, onasemnogene abeparvovec]
-
A.
approvedAt
Indicates the date and time at which an entity received formal approval.
-
B.
approvedBy
Indicates that an action, request, or item has received formal authorization or consent from a specified entity.
-
C.
approvedAs
Indicates that one entity has been officially accepted, authorized, or validated in a particular role, status, or capacity by another entity.
-
D.
approvalFor
chosen
Indicates that one entity grants or has granted permission or consent for another entity’s action, request, or status.
-
E.
approvalStatus
Indicates the current state of authorization or acceptance granted to an entity or action.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
| PD | Predicate disambiguation | batch_69eed2c32e8c8190b73bb9965ed47d64 |
completed | April 27, 2026, 3:06 a.m. |
Created at: April 17, 2026, 3:30 p.m.